V
1.86
-0.06 (-2.92%)
| Penutupan Terdahulu | 1.92 |
| Buka | 1.91 |
| Jumlah Dagangan | 33,195 |
| Purata Dagangan (3B) | 271,458 |
| Modal Pasaran | 3,355,020 |
| Harga / Jualan (P/S) | 20.23 |
| Harga / Buku (P/B) | 7.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 May 2025 - 2 Jun 2025 |
| Margin Operasi (TTM) | -14,450.00% |
| EPS Cair (TTM) | -10.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 380.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 291.21% |
| Nisbah Semasa (MRQ) | 0.710 |
| Aliran Tunai Operasi (OCF TTM) | -10.10 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.72 M |
| Pulangan Atas Aset (ROA TTM) | -123.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -378.40% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | VivoSim Labs, Inc. | - | - |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.53% |
| % Dimiliki oleh Institusi | 12.21% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 May 2025 | Pengumuman | VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference |
| 07 May 2025 | Pengumuman | VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference |
| 23 Apr 2025 | Pengumuman | VivoSim to Carry Forward Organovo 3D Bioprinting |
| 02 Apr 2025 | Pengumuman | Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements |
| 27 Mar 2025 | Pengumuman | Organovo Provides Business Update |
| 25 Mar 2025 | Pengumuman | Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company |
| 19 Mar 2025 | Pengumuman | Organovo Announces Reverse Stock Split |
| 06 Mar 2025 | Pengumuman | Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |